4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

4D Molecular Therapeutics

11/08/2025 13:55

4D Molecular Therapeutics Inc FDMT.OQ reported a quarterly adjusted loss of 98 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -63 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 88 cents per share. Wall Street expected results to range from $-1.04 to -78 cents per share.

Revenue rose 200% to $15.00 thousand from a year ago; analysts expected $374.14 thousand.

4D Molecular Therapeutics Inc's reported EPS for the quarter was a loss of 98 cents​.

The company reported a quarterly loss of $54.66 million.

4D Molecular Therapeutics Inc shares had risen by 51.8% this quarter and gained 1.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $30.00, about 81.2% above its last closing price of $5.63

This summary was machine generated from LSEG data August 11 at 12:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.88
-0.98
Missed
Mar. 31 2025
-0.86
-0.86
Met
Dec. 31 2024
-0.82
-0.90
Missed
Sep. 30 2024
-0.70
-0.79
Missed